Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06962891
Active, not recruiting Observational

Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease

NCT06962891 · tracked via the Priya Life Science France tracker
Sponsor
Angel Argiles
Phase
Observational
Started
2023-05-02
Last updated
2025-07-24

Condition(s) studied

Chronic Kidney Disease(CKD)Progression, Disease

Investigational drug(s) / intervention(s)

CKD progression biomarker

CKD progression biomarker: We will evaluate the CKD progression biomarker at baseline and evaluate 1-year CKD progression afterwards.

Study summary

The goal of this longitudinal observational study is to estimate the performances of a candidate proteomic biomarker to identify patients at short term risk of chronic kidney disease (CKD) progression, in CKD patients attending nephrology visits in 3 participating centres. The primary endpoint of CKD progression is defined as a relative change in eGFR observed at 1 year below -10%. The performance of the candidate biomarker will be compared to performances of UAE and KFRE equations.

Participants will attend two study visits (baseline and 1-year), with clinical evaluation including kidney parameters (eGFR, urinary albumin excretion (UAE)) and collection of biological samples (plasma, serum, urine) for candidate proteomic biomarker evaluation. If planned in routine, patients will also have creatinine clearance estimation from 24-hour urine collection, kidney echography and kidney biopsy, sample biobanking and/or questionnaires and interviews on social and ethical aspects.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female patients * over 18 years and below 85 years of age at recruitment * Chronic kidney disease (CKD) * eGFR of 25-65 mL/min/1.73m2 (CKD-EPI formula) * Beneficiary of health insurance * Must be able to communicate with the investigator * Written informed consent must be provided before participation. Exclusion Criteria: * History of renal transplantation * Current episode of Acute Kidney Injury * Any clinically significant disorder, which in the Investigator's opinion could interfere with the results of the trial. * Known or suspected abuse of alcohol or narcotics * Current pregnancy * Inability to give written informed consent * Protected adults

Primary outcome measure(s)

  • Relative eGFR change — 1 year
    Difference in eGFR after 1-year divided by baseline eGFR estimated with CKD-EPI formula

Trial sites (3)

FacilityCityRegionStatus
Medizinische Universität Innsbruck Innsbruck Austria
Néphrologie Dialyse St Guilhem Sète France
Klinikum Bayreuth GmbH Bayreuth Germany

Other trials for the same condition

Prevalence and Severity of Cramps in Chronic Kidney Disease Patients Starting soon
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06962891 on ClinicalTrials.gov ↗ ← All trials in France